{"id":336417,"date":"2025-08-11T18:45:10","date_gmt":"2025-08-11T18:45:10","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/336417\/"},"modified":"2025-08-11T18:45:10","modified_gmt":"2025-08-11T18:45:10","slug":"three-new-cancer-drugs-approved-for-use-for-nhs-scotland-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/336417\/","title":{"rendered":"Three new cancer drugs approved for use for NHS Scotland"},"content":{"rendered":"

Three new treatments for cancer have been approved for use by the NHS in Scotland.<\/strong><\/p>\n

The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness.<\/p>\n

However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma \u2013 an uncommon cancer that develops in the lymphatic system.<\/p>\n

SMC vice chair Graeme Bryson said the treatment could \u201chelp increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse\u201d.<\/p>\n

Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma \u2013 a rare type of the blood cancer non-Hodgkin lymphoma.<\/p>\n

The SMC has also approved the drug ripretinib \u2013 also known as Qinlock \u2013 to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system.<\/p>\n

In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn\u2019s disease, a lifelong condition which is a chronic inflammatory bowel disease.<\/p>\n

However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments.<\/p>\n

Mr Bryson said: \u201cThe committee is pleased to be able to accept these new medicines for use by NHS Scotland.<\/p>\n

\u201cBrentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse.<\/p>\n

\u201cRipretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available.<\/p>\n

\u201cZanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment.<\/p>\n

\u201cMirikizumab offers an additional treatment option for people with moderate to severe Crohn\u2019s disease whose disease is not controlled on standard or biologic treatment.\u201d<\/p>\n

However he added: \u201cThe committee was unable to accept dupilumab for treating patients with COPD as the company\u2019s evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.\u201d<\/p>\n

STV News is now on WhatsApp<\/p>\n

Get all the latest news from around the country<\/p>\n

Follow STV News <\/a>Follow STV News on WhatsApp<\/p>\n

Scan the QR code on your mobile device for all the latest news from around the country<\/p>\n

\"WhatsApp<\/p>\n","protected":false},"excerpt":{"rendered":"Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines…\n","protected":false},"author":2,"featured_media":336418,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,16,15],"class_list":{"0":"post-336417","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115011618409146357","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/336417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=336417"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/336417\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/336418"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=336417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=336417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=336417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}